Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
76
INDV Quote, Financials, Valuation and Earnings
Last price:
$33.89
Seasonality move
:
4.05%
Day range:
$33.85 - $34.94
52-week range:
$7.62 - $38.00
Dividend yield:
0%
P/E ratio:
33.74x
P/S ratio:
3.63x
P/B ratio:
238.64x
Volume:
1.5M
Avg. volume:
1.8M
1-year change:
276.97%
Market cap:
$4.2B
Revenue:
$1.2B
EPS (TTM):
$1.00
Analysts' Opinion
-
Consensus RatingIndivior Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.57, Indivior Pharmaceuticals, Inc. has an estimated upside of 34.47% from its current price of $33.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $33.89.
Fair Value
-
According to the consensus of 5 analysts, Indivior Pharmaceuticals, Inc. has 34.47% upside to fair value with a price target of $45.57 per share.
INDV vs. S&P 500
-
Over the past 5 trading days, Indivior Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Indivior Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Indivior Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Indivior Pharmaceuticals, Inc. reported revenues of $314M.
Earnings Growth
-
Indivior Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Indivior Pharmaceuticals, Inc. reported earnings per share of $0.33.
Enterprise value:
4.1B
EV / Invested capital:
--
Price / LTM sales:
3.63x
EV / EBIT:
12.46x
EV / Revenue:
3.52x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
31.06x
Price / Operating cash flow:
32.04x
Enterprise value / EBITDA:
11.83x
Gross Profit (TTM):
$1B
Return On Assets:
9.03%
Net Income Margin (TTM):
10.76%
Return On Equity:
14.29%
Return On Invested Capital:
130.39%
Operating Margin:
31.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1B | $1.2B | $1.2B | $307M | $314M | |
| Gross Profit | $847M | $946M | $1B | $241M | $252M | |
| Operating Income | -$299M | $254M | $333M | $77M | $99M | |
| EBITDA | -$276M | $280M | $350.6M | $85M | $104M | |
| Diluted EPS | -$1.74 | $0.27 | $1.00 | $0.17 | $0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $1.3B | $1.2B | $799M | $921M | |
| Total Assets | $1.7B | $1.7B | $1.9B | $1.5B | $1.4B | |
| Current Liabilities | $712M | $744M | $1.2B | $962M | $965M | |
| Total Liabilities | $1.5B | $1.4B | $1.9B | $1.6B | $1.6B | |
| Total Equity | $161M | $227M | -$24M | -$167M | -$207M | |
| Total Debt | $288M | $276M | $277M | $284M | $346M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.8M | -$227.4M | $193.5M | $3.1M | -$41.8M | |
| Cash From Investing | -$107.7M | $67.2M | -$35M | $35.2M | -$20.5M | |
| Cash From Financing | -$52.8M | -$165.5M | $4.4M | -$53.8M | -$3M | |
| Free Cash Flow | -$87.2M | -$259.6M | $133.5M | -$4.2M | -$62.2M | |
INDV
Sector
Market Cap
$4.2B
$25.5M
Price % of 52-Week High
89.18%
49.47%
Dividend Yield
0%
0%
Shareholder Yield
1.41%
-1.77%
1-Year Price Total Return
276.97%
-21.96%
Beta (5-Year)
1.134
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$34.17
200-day SMA
Buy
Level
$24.72
Bollinger Bands (100)
Buy
Level
27.33 - 36.11
Chaikin Money Flow
Buy
Level
75.2M
20-day SMA
Sell
Level
$34.35
Relative Strength Index (RSI14)
Sell
Level
46.17
ADX Line
Buy
Level
10.25
Williams %R
Neutral
Level
-74.3056
50-day SMA
Sell
Level
$34.85
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
118.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5923)
Sell
CA Score
(Annual)
Level (-2.4283)
Buy
Beneish M-Score
(Annual)
Level (-2.6971)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-28.827)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.
Stock Forecast FAQ
In the current month, INDV has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INDV average analyst price target in the past 3 months is $45.57.
-
Where Will Indivior Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Indivior Pharmaceuticals, Inc. share price will rise to $45.57 per share over the next 12 months.
-
What Do Analysts Say About Indivior Pharmaceuticals, Inc.?
Analysts are divided on their view about Indivior Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Indivior Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $36.00.
-
What Is Indivior Pharmaceuticals, Inc.'s Price Target?
The price target for Indivior Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $45.57 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INDV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Indivior Pharmaceuticals, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INDV?
You can purchase shares of Indivior Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Indivior Pharmaceuticals, Inc. shares.
-
What Is The Indivior Pharmaceuticals, Inc. Share Price Today?
Indivior Pharmaceuticals, Inc. was last trading at $33.89 per share. This represents the most recent stock quote for Indivior Pharmaceuticals, Inc.. Yesterday, Indivior Pharmaceuticals, Inc. closed at $33.89 per share.
-
How To Buy Indivior Pharmaceuticals, Inc. Stock Online?
In order to purchase Indivior Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get INDV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INDV
Sector
P/E ratio
33.74x
23.41x
PEG ratio
0.13x
-0.01x
P/B ratio
238.64x
1.78x
Price / LTM sales
3.63x
1.56x
Growth Metrics
INDV
Sector
Revenue growth
2.28%
3.51%
Earnings growth
96.86%
9.95%
Revenue (5-year growth)
8.64%
6.45%
Earnings forecast
$0.67
-$0.19
Profitability
INDV
Sector
Profitability FY 2024
$998M
$2.6M
Return on invested capital
130.39%
-33.25%
Return on assets
9.03%
-29.68%
Return on equity
14.29%
-38.71%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Jan
29
Balance Sheet
INDV
Sector
Total cash
$445M
$25M
Short term investments
$1M
$24M
Total assets
$1.3B
$71.9M
Long term debt
$346M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
